IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3011% above fair value
$0.19+0.01 (+7.37%)
Close on Nov 17, 2026Market cap $19.43MP/E –Yield –
IGC Pharma r&d expenses
Research and development expenses are spending on new products and technology.
IGC Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.73M, up 58.5% year over year. For fiscal 2025 it was $3.66M, down 3.1% from the year before. The highest annual figure on record is $3.77M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.66M | -3.1% |
| FY2024 | Mar 31, 2024 | $3.77M | +9.0% |
| FY2023 | Mar 31, 2023 | $3.46M | +48.5% |
| FY2022 | Mar 31, 2022 | $2.33M | +150.8% |
| FY2021 | Mar 31, 2021 | $929.00K | -8.1% |
| FY2020 | Mar 31, 2020 | $1.01M | -19.5% |
| FY2019 | Mar 31, 2019 | $1.26M | +816.8% |
| FY2018 | Mar 31, 2018 | $137.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $1.39M | +63.3% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $1.27M | +27.6% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $1.48M | +73.9% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $1.59M | +73.2% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $851.00K | -4.3% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $997.00K | +16.6% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $852.00K | -5.6% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $917.00K | -27.7% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $889.00K | +19.0% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $855.00K | +73.4% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $903.00K | +12.0% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $1.27M | +65.1% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $747.00K | -46.4% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $493.00K | -60.0% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $806.00K | +113.8% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $768.00K | +178.3% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $1.39M | +214.0% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $1.23M | +269.2% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $377.00K | +144.8% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $276.00K | +26.0% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $444.00K | +100.0% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $334.00K | +35.2% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $154.00K | -47.8% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $219.00K | -1.4% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $222.00K | -10.1% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $247.00K | -69.5% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $295.00K | +77.7% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $222.00K | -20.1% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $247.00K | +586.1% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $811.00K | +926.6% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $166.00K | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $278.00K | +256.4% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $36.00K | -36.3% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $79.00K | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $0 | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $78.00K | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $56.54K | – |
See a number that looks wrong?